Home › Funds › Stonepine Capital Management, LLC › RARE

Stonepine Capital Management, LLC position in RARE

ULTRAGENYX PHARMACEUTICAL IN · Health Care

Stonepine Capital Management, LLC reported holding 100,000 shares of RARE (ULTRAGENYX PHARMACEUTICAL IN) in its Q3 2026 13F filing — a position valued at US$3.0M, representing 2.30% of its reported portfolio and ranking #13 among its reported holdings. Stonepine Capital Management, LLC has disclosed RARE holdings in 4 of the last 5 reported quarters, going back to Q3 2025.

Latest position (Q3 2026)100.00K sh
Reported value held$3.00M
Portfolio Weight2.30%
First reportedQ3 2025
Last changeAdd
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Stonepine Capital Management, LLC's RARE position evolved

Stonepine Capital Management, LLC first disclosed a stake in RARE in Q3 2025 at 20,000 shares (US$602K). The position peaked in Q3 2026 at 100,000 shares, worth US$3.0M. Across 4 filings, Stonepine Capital Management, LLC increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 100,000 shares valued at US$3.0M — an increase of 75,000 shares quarter over quarter.. Notable position changes include a 400% increase in Q4 2025 (shares fell 9% over the following quarter), a 300% increase in Q3 2026 (shares rose 7% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2025 20.00K $601.60K New
Q4 2025 100.00K $2.30M Add
Q2 2026 25.00K $834.75K New
Q3 2026 100.00K $3.00M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RARE and 13F data

RARE (ULTRAGENYX PHARMACEUTICAL IN) is a Health Care company. 24 other funds we track also report a position in RARE — the largest reported positions include RTW INVESTMENTS, LP (US$260.3M), FRONTIER CAPITAL MANAGEMENT CO LLC (US$95.1M), Bellevue Group AG (US$66.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RARE

All RARE fund holders →

FAQ

How long has Stonepine Capital Management, LLC held RARE?

Stonepine Capital Management, LLC has disclosed RARE holdings in 4 of the last 5 reported quarters, going back to Q3 2025.

What is Stonepine Capital Management, LLC's current position in RARE?

As of Q3 2026, Stonepine Capital Management, LLC holds 100.00K shares of RARE (ULTRAGENYX PHARMACEUTICAL IN), valued at $3.00M, representing 2.30% of its reported portfolio and ranking #13.

Has Stonepine Capital Management, LLC been buying or selling RARE?

In the latest 13F filing (Q3 2026), Stonepine Capital Management, LLC increased its position in RARE. The position peaked in Q3 2026 at 100.00K shares.

Which other funds hold RARE?

Other major institutional holders of RARE include RTW INVESTMENTS, LP, FRONTIER CAPITAL MANAGEMENT CO LLC, Bellevue Group AG, among 24 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.